Spots Global Cancer Trial Database for Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker
Official Title: Prospective Characterization of Tumor-specific T-cell Immunity in Muscle-invasive Bladder Cancer and Its Correlation With Clinical Parameters
Study ID: NCT01198808
Conditions
Interventions
Study Description
Brief Summary: Bladder cancer is generally susceptible to immunotherapeutic measures. The investigators will characterize 40 patients with muscle-invasive bladder cancer regarding the existence and frequency of tumorspecific T-cells and regulatory T cells. The found data will be correlated to clinical data such as the cancer-specific survival and the response to chemotherapy. It is hypothesized that those patients with a high number of Tregs and no tumor-specific T-cells have a worse prognosis.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
Urologische Klinik der Technischen Universität München, Munich, Bavaria, Germany
Contact Details
Name: Thomas Horn, MD
Affiliation: Department of Urology, Technische Universität München
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
